Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China
Study Identifier:
D7413C00001
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Recruitment Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Eculizumab
Date
Jul 2023 - May 2025
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A
Requirements Information
Sex
Female & Male
Age
N/A - N/A
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Eculizumab
Date
Jul 2023 - May 2025
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A years
Requirements Information
Protocol Summary
This is a Phase 3b, open-label, single-arm, multicenter study to evaluate the efficacy and safety of eculizumab in participants with atypical hemolytic uremic syndrome (aHUS) in China
Trial Locations
Location
Status
Location
Research Site
Beijing, China, 100034
Status
N/A
Location
Research Site
Beijing, China, 100045
Status
N/A
Location
Research Site
Changsha, China, 410007
Status
N/A
Location
Research Site
Qingdao, China, 110016
Status
N/A
Location
Research Site
Taiyuan, China, 030012
Status
N/A
Location
Research Site
Wuhan, China, 430030
Status
N/A